Latest News and Press Releases

Alkeus Pharmaceuticals presents gildeuretinol data during the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting May 4-8, 2025

Alkeus Pharmaceuticals announces presentations of gildeuretinol data in Stargardt and GA during ARVO May 4-8

CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of individuals impacted by retinal diseases, today...

CAMBRIDGE, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of individuals impacted by retinal diseases, today...

Two additional TEASE-3 participants who recently completed 24 months of therapy showed no disease progression, consistent with prior results. A total of five patients have completed the 24-month...

Alkeus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14.

CAMBRIDGE, Mass., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc. today announced that results from its clinical studies of investigational oral gildeuretinol for the treatment of...

Alkeus Pharmaceuticals, Inc. receives FDA Rare Pediatric Disease and Fast Track designations for gildeuretinol as a treatment for Stargardt Disease

Alkeus Pharmaceuticals appoints David Arkowitz as Chief Financial Officer.

Alkeus Pharmaceuticals, Inc., today announced that results from its study of gildeuretinol in geographic atrophy were presented at AAO 2024.